Eric Hockstad, MD
Interventional Cardiology · Kansas City, KSNPI 1053364265
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Abbott accounts for 64.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $9,030 and has fallen 89.0% since, to $997 in 2025.
Across 160 payments — averaging $92.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Medtronic$2K
- Boston Scientific$1K
- Amgen$278
- Biosense Webster, Inc.$271
- Philips North America LLC$251
- plus $1K from 21 others
Across 10 payments — averaging $2315.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$23K
What the payments were for
- Consulting fees$8,09255%
- Food & beverage$6,64045%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 28 | $9,456 |
| Medtronic(2 entities) | 24 | $1,716 |
| Boston Scientific | 27 | $1,308 |
| Amgen | 16 | $278 |
| Biosense Webster, Inc. | 3 | $271 |
| Philips North America LLC | 4 | $251 |
| Abiomed | 5 | $225 |
| E.r. Squibb & Sons, L.L.C. | 12 | $205 |
| Edwards Lifesciences | 1 | $161 |
| Cardiva Medical, Inc. | 1 | $126 |
| Shockwave Medical, Inc | 2 | $121 |
| AstraZeneca | 8 | $119 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Novo Nordisk | 2 | $44 |
| Pfizer | 3 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $41 |
| Merck | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $36 |
| W. L. Gore & Associates, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Penumbra, Inc. | 1 | $25 |
| Endotronix, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Bayer | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$8,357
- RESOLUTE ONYX$757
- QDOT MICRO Catheter$253
- Watchman$244
- XIENCE SKYPOINT$172
- COROFLOW$165
- Xience Sierra Coronary Stent System$164
- Impella$147
- WATCHMAN Access System$139
- OPTIS$131
- AMPLATZER AMULET$129
- WATCHMAN FLX$129
- Cardiva VASCADE 6/7F VCS$126
- AVVIGO Guidance System$123
- Resolute$116
- GENERAL ATHERECTOMY$114
- (AO0) IGT Devices Intracardiac$108
- COBALT DR MRI SURESCAN$106
- (6571) Eagle Eye$102
How this compares
$14,765 in reported general payments places this provider in the 65th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $245,857 |
| Repatha SureclickEvolocumab | 271 | $166,874 |
| XareltoRivaroxaban | 40 | $41,682 |
| Praluent PenAlirocumab | 70 | $35,096 |
| EntrestoSacubitril/Valsartan | 16 | $16,011 |
| Ezetimibe | 261 | $6,804 |
| Rosuvastatin Calcium | 289 | $3,886 |
| Atorvastatin Calcium | 383 | $3,270 |
| Metoprolol Succinate | 182 | $2,302 |
| Losartan Potassium | 257 | $2,080 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 66 | $1,947 |
| Chlorthalidone | 104 | $1,897 |
| ClopidogrelClopidogrel Bisulfate | 144 | $1,873 |
| Flecainide Acetate | 23 | $1,655 |
| Amlodipine Besylate | 189 | $1,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $245,857228 claims |
| Johnson & JohnsonXarelto | $30 | $41,68240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Kansas City
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- John SerfasKansas City$31K
- Venkat PasnooriKansas City$21K
- Peter TadrosKansas City$20K
- Georges HajjKansas City$5K
- Ashwani MehtaKansas City$4K
- Maheedhar GedelaWichita$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.